Senti Biosciences, Inc.

Senti Biosciences, Inc. reported a net loss of $61.4 million for the fiscal year ended December 31, 2025, compared to a net loss of $52.8 million in the prior year. The company generated minimal collaboration revenue of $22 thousand from a related party. Operating expenses totaled $68.8 million, primarily driven by research and development costs of $37.6 million and general and administrative expenses of $26.2 million. The company's cash position declined significantly, with cash and cash equivalents falling to $16.4 million from $48.3 million at the end of 2024, raising substantial doubt about its ability to continue as a going concern. The company's lead product candidate, SENTI-202, received Orphan Drug and RMAT designations from the FDA in 2025.

Key Takeaways